Shanghai, July 24, 2018: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Antengene Corporation, a…
WuXi STA enables Ascletis to receive NDA Approval from China FDA for Ganovo® Shanghai, June 15, 2018: STA Pharmaceutical Co., Ltd. (WuXi…
The integrated R&D and manufacturing facility is expecting more products to go into commercial production post approval Shanghai, May 11,…
New Delhi, April 30, 2018: WuXi STA has already established an industry leading process development platform with over 1,000 scientists…
MD-026 is the first RSK inhibitor to demonstrate potential disease-modifying properties in triple-negative breast cancer (TNBC) Vancover, April 19, 2018: Phoenix…
Agreement follows the recent opening of WuXi STA’s oligonucleotide R&D labs in China and the USA. Shanghai, May 03, 2018: STA…